Clinerion is part of Citeline, a Norstella company!
January 30, 2023 – Clinical Trials –
January 30, 2023 – We are pleased to officially announce that Clinerion has become part of Citeline, a Norstella company. Norstella is now poised to be one of the worldís largest pharma intelligence solutions providers on the market.
With the integration into Citeline, Clinerion has the opportunity to access tools and services complementary to our own, expanding the portfolio of offers, as well as access to experts and expertise along the entire clinical intelligence, planning, development and trials process streams. This will allow us to continue to develop cutting-edge technologies and expand our real-world data network.
Our joining Citeline and the Norstella group is excellent news for you, our partners and customers, who will benefit from our combined expertise, a wider portfolio of products, faster innovation, and enhanced capabilities, providing even greater value to your business over time. In the meantime, Clinerion will continue to provide the outstanding customer service you have come to expect, and your interaction with our business will continue as usual.
Clinerion CEO, Barış Erdoğan, had this to say:
“2022 was a big year for Clinerion. Besides the incredible growth in our global real-world data network and our continuing development of cutting-edge technologies, we also had one further piece of news that we have held back until now!
We are pleased to officially announce that Clinerion has become part of Citeline, and that Citeline became a Norstella company on the 31st of October, 2022. Comprised of four prominent pharmaceutical solutions providers you may already be familiar with, Evaluate, MMIT, Panalgo, The Dedham Group and of course, Citeline, Norstella is now poised to be one of the worldís largest pharma intelligence solutions providers on the market.
With the integration into Citeline, Clinerion has the opportunity to access tools and services complementary to our own, expanding the portfolio of offers, as well as access to experts and expertise along the entire clinical intelligence, planning, development and trials process streams. This will allow us to continue to develop cutting-edge technologies and expand our real-world data network.
Clinerion has hit historic milestones recently, reaching global real-world data coverage on Patient Network Explorer of 426 M patients in 10,340 healthcare organisations and trial sites, in 24 countries, in 2022. We also launched our Federated Machine Learning Platform and secured the patent for our ANID de-identification technology.
Patients remain at the center of everything we do, and we are committed to continuing our efforts to accelerate bringing innovative medical interventions to patients and physicians around the world through use of our patented technologies.
Our joining Citeline and the Norstella group is excellent news for you, our partners and customers, who will benefit from our combined expertise, a wider portfolio of products, faster innovation, and enhanced capabilities, providing even greater value to your business over time. In the meantime, Clinerion will continue to provide the outstanding customer service you have come to expect, and your interaction with our business will continue as usual.
Weíre excited to share more news with you as we continue to develop transformative solutions to meet our clientsí needs, but in the interim, we want to thank you for your continued partnership and support. Without such committed clients, we would not be able to achieve our mission of improving patient access to life-saving therapies.”
